Your AI-Trained Oncology Knowledge Connection!
Experts review recent evidence shaping prostate cancer care, including emerging survival data, sion outcomes, and findings across biochemical recurrence and metastatic castration-sensitive prostate cancer.
Experts discuss practical management considerations, including patient selection for monotherapy, long term tolerability, fatigue management strategies, and the role of exercise in supporting patients on therapy.
Experts explore how alterations within the PI3K/AKT/PTEN pathway influence treatment decisions in HR+/HER2-negative advanced breast cancer, and we will take a focused look at strategies for managing key adverse events associated with therapies targeting this pathway, including diarrhea, hyperglycemia, and rash.
Experts integrate perspectives from medical oncology, pharmacy, and advanced practice nursing to review practical approaches to patient education, monitoring, and supportive care, along with considerations that support treatment adherence and improve patient experience.
Breast cancer experts discuss how long-term data from the monarchE and NATALEE trials inform patient selection, drug choice, and real-world use of adjuvant CDK4/6 inhibitors in high-risk HR-positive, HER2-negative early breast cancer.
Experts examine the evolving role of TROP2 in non–small cell lung cancer, highlighting the limitations of conventional IHC and the potential of quantitative continuous scoring (QCS) and normalized membrane ratio (NMR) as more reliable, predictive biomarkers for TROP2-directed antibody–drug conjugates.
This OncLive Insights program features Drs. Sandip Patel and Jonathan Riess in an in-depth discussion on current and emerging strategies for managing HER2-mutated non-small cell lung cancer (NSCLC). The experts review the evolving diagnostic landscape, emphasizing the importance of comprehensive molecular testing, both tissue and plasma, to identify HER2 mutations and HER2 IHC 3+ overexpression. They examine the clinical integration of targeted therapies including trastuzumab deruxtecan (T-DXd), zongertinib, and the recently reported sevabertinib, highlighting their efficacy, safety profiles, and roles across lines of therapy. Key challenges are addressed, such as CNS metastases, sequencing uncertainty, toxicity monitoring, and the need for resistance-based treatment strategies. The discussion concludes with a forward-looking perspective on next-generation HER2 inhibitors, ADC development, CNS-penetrant agents, and opportunities to advance care through clinical trials and real-world evidence.
